STING1 and neoplasm: A recent study by Froechlich and colleagues demonstrated that a functional cGAS/STING pathway was essential to trigger anti-tumor adaptive immune responses in immunocompetent preclinical models, and thus it was considered a prerequisite for sustaining the immunotherapeutic efficacy of oncolytic HSVs [90].